Patent intelligence · US
US 11110093
Sustained release small molecule drug formulation
Sustained release small molecule drug formulation
Patent details — US 11110093
- Jurisdiction
- US
- Status
- granted
- Grant date
- Sep 7, 2021
- Expiration
- Sep 2, 2041
- Applicant
- Indivior UK Limited
- Claims
- 20
- CPC classes
- A61K, A61K31/341, A61K31/519, A61K47/10
Quick answer
US 11110093 (Sustained release small molecule drug formulation) is held by Indivior UK Limited. Status: granted. Granted Sep 7, 2021. Expires Sep 2, 2041 (15 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Indivior UK Limited
- Grant date
- Expiration
- Claims
- 20
- CPC classes
- A61K, A61K31/341, A61K31/519, A61K47/10, A61K47/14, A61K47/22
More from Indivior UK Limited
Related pharmaceutical patents in our USPTO index.
-
US 12290596
Compositions and methods for the treatment of opioid overdose
granted -
US 11839611
Buprenorphine dosing regimens
granted -
US 11712475
Sustained delivery formulations of risperidone compound
granted -
US 11135216
Sublingual and buccal film compositions
granted -
US 11013809
Sustained delivery formulations of risperidone compound
granted -
US 11000520
Buprenorphine dosing regimens
granted -
US 10654842
Dopamine D3 receptor antagonist compounds
granted
Frequently asked questions
What is US patent 11110093?
US 11110093 (Sustained release small molecule drug formulation) is held by Indivior UK Limited. Status: granted. Granted Sep 7, 2021. Expires Sep 2, 2041 (15 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11110093?
Indivior UK Limited is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 34 pharmaceutical patents for this assignee.
When does US 11110093 expire?
Our index shows an expiration date of Sep 2, 2041 (15 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.